Symbiomix Therapeutics Private
Symbiomix is a late-stage, privately-held biopharmaceutical company developing innovative medicines for serious womenвАЩs health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the worldвАЩs leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences, and HBM Partners. The CompanyвАЩs lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next-generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.
%20.jpg)
Industry:
PharmTech
Technology:
Cancer
Funding Status:
M&A
Investment Stage:
N/A
Estimated Revenue:
$10M to $50M
Investors Number:
5
Headquarters:
Newark, New Jersey, United States
Employee Number:
11-50
Number Of Exists:
Venture - Series Unknown
Investor Type:
Company
Total Funding:
$47 000 000
Founded Date:
2012
Last Funding Type:
Venture - Series Unknown
Last Funding Date:
2018-01-01